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Abstract: Advances in food and nutrition sciences highlighted that diet can provide consumers with components able to 
both modulate body functions, improve health status and wellbeing and/or reduce the risk of some diseases. Therefore, 
much research has been undertaken in recent years on development and application of technologies to develop functional 
foods. Functional foods and dietary supplements can make health claims and/or structure/function claims. Health claims 
state that an ingredient may reduce the risk of a disease, whereas, structure/function claims declare that an ingredient in 
the product could benefit a body’s structure (the skeletal system) or its function (the circulatory system). This paper in-
cludes information on the common products rich in nutraceutic components; explains the importance of probiotic and pre-
biotic foods and finally focuses on recent patents dealing with functional formulations for specific human diseases. 
Keywords: Functional components, prebiotic, probiotic, functional food, nutrigenomics, health benefit. 
1. INTRODUCTION 
 With increase use of dietary supplements and functional 
foods, questions have arisen about whether these products 
are safe to use and actually provide the health benefits they 
claim (United States General Accounting Office Washing-
ton, D.C. 20548 July 11, 2000). The International Food In-
formation Service (USA) defines the functional foods as 
'foods that provide benefits beyond basic nutrition' [1].  
 In the past, food technology has not been an area of fre-
quent patenting relative to technologies that impact the nu-
traceutical and functional food markets, such as formulation 
science. Although patenting of food technologies is now on 
the rise, most of the filings are classified under those of 
medicines and usually cover processes such as extraction or 
purification rather than bare end product and therefore  
results in the FDA (US Food and Drug Administration) treat-
ing the products as drugs. To date, the FDA has only author-
ized health claims that reduce the risk of a disease. Interest-
ingly, the FDA regulates nutraceuticals less stringently than 
foods in terms of what health claims can be made [2]. There 
is no FDA regulatory policy specific to functional foods; 
rather they are regulated under the same framework as con-
ventional foods (Scientific substantiation of claims in the 
USA: focus on functional foods). 
 Both functional foods and dietary supplements can make 
health claims and/or so-called structure/function claims. 
Health claims state that an ingredient may reduce the risk of 
a disease whereas structure/function claims declare that an 
ingredient in the product will benefit a body’s structure (such 
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as the skeletal system) or function (such as the circulatory 
system) (United States General Accounting Office Washing-
ton, D.C. 20548 July 11, 2000). Japanese researchers intro-
duced the term “functional food” more than twenty-five 
years ago, but the concept still lacks a uniform definition. 
The first book on this topic, [3] considers as functional ‘‘any 
food that has a positive impact on an individual health, 
physical performance, or state of mind in addition to its nu-
tritive values’’. In other words, in addition to the bulk ingre-
dients and calories that one consumes when eating food, a 
functional food has to deliver an additional beneficial effect 
on health or wellbeing. The Journal of Agricultural and En-
vironmental Ethics [4] states that the two key aspects in the 
evaluation of functional foods are safety and efficacy. While 
safety can be covered under different legislative umbrellas 
such as novel foods (NFs), foods for particular nutritional 
purposes, supplements, additives and others, the issue of 
evaluation of their efficacy is only at a very early stage since 
the criteria to establish the validity of ‘health claims’ has not 
been clearly addressed at the European level. In addition, the 
European Journal of Clinical Nutrition [5] states that a func-
tional food contains a component (whether or not a nutrient) 
that allows one to obtain benefits on body functions and 
physical wellbeing, psychological effect or reducing risk of 
disease. A group of European experts (Madrid, October 
1998) adopted the following definition: “a food can be re-
garded as functional if it is satisfactorily demonstrated to 
affect beneficially one or more target functions in the body, 
beyond adequate nutritional effects in a way which is rele-
vant to either the state of well-being and health or the reduc-
tion of the risk of a disease”. A functional food contains 
macronutrients or essential micronutrient for specific physi-
ologic effects. It can also be stated that a food is functional if 
(i) it allows the elimination of known components that cause 
deleterious effects when consumed (e.g., an allergenic pro-
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tein); (ii) increases the concentration of a component natu-
rally present in food to induce predicted beneficial effects 
(fortification with a micronutrient to reach a daily intake 
higher than the recommended daily intake but compatible 
with the dietary guidelines for reducing risk of disease); (iii) 
contains a component with known beneficial effects that is 
not normally present in most foods (e.g., non-vitamin anti-
oxidant or prebiotic fructans); (iv) replaces a component 
(e.g., fats) whose intake is usually excessive, and thus repre-
sents a cause of deleterious effects, by a component for 
which beneficial effects have been shown (e.g., chicory  
); (v) increases the stability of a component known to reduce 
the potential disease-risk of the food [6]. 
 Sustainability is a concept that emerged from the World 
Commission on Environment and Health (1987) and was 
developed further at the Earth Summit in Rio De Janeiro in 
1992. Now it is even more broadly defined, extending be-
yond the status of resources to the health of communities, 
consumer empowerment and equity of access to material 
resources. Applications of this concept provide guidelines 
for decision-making and framework for assessing the impact 
of all initiatives. Given the food–environment–health links it 
embraces, it is particularly appropriate for assessing the im-
pact of food-producing systems on individuals, communities 
and environment. Despite the developments, there are dis-
crepancies between producers and consumers understanding 
and application of the concept of sustainability to systems of 
food supply [7]. So, assessing the sustainability of any type 
of food or food-related practice is problematic. Nonetheless, 
it is possible to list a range of criteria that can be applied to 
evaluate the sustainability of food systems, including func-
tional foods. 
 In the first instance, food must provide nutrients and en-
ergy required to sustain wellbeing and reduce risks to physi-
cal health. The social dimensions of health require that indi-
viduals have the opportunities to express themselves and 
identify with others processes often involving the sharing of 
food. So, health is determined by the accessibility of food to 
consumers, and the opportunities for food choice, which 
translate to affordability, availability, variety and cultural 
relevance of food. They need to be able to decide the most 
cost effective way to protect their health when making food 
choices. This assumes that consumers are motivated and 
capable of accessing reliable information about the choices 
available to them, with implications for the ways complex 
science is translated into food labeling, advertising and other 
communications. In a sustainable system, consumers can 
influence decisions about food production as new scientific 
information about nutrition, their health needs and the envi-
ronment emerges. Finally, producing functional foods must 
be cost effective in conventional terms, by comparing the 
resources consumed relative to the benefits they provide. 
2. MAIN SOURCES OF FUNCTIONAL COMPO-
NENTS 
 Cereals, legumes, fruit and vegetables are common prod-
ucts rich in nutraceutic components. Table 1 reports a sum-
mary of the other main functional components of foods and 
their benefits. At present gut health products in particular 
probiotics and prebiotics dominated the market of functional 
foods.  
 Probiotics are defined as live microbial food supplement 
that if consumed in adequate quantity can have beneficial 
effects improving the microbiological balance in the intes-
tine. The microbial community in the large intestine is ex-
tremely complex, both in terms of the number of organisms, 
approximately 10
13
 cells/g contents in total, and in its diver-
sity, with over 400 different species reported. This complex 
and highly adapted community also provides further benefits 
increasing resistance to pathogens. Because the native gut 
microflora are so well adapted to their environment, it is 
difficult for other organisms (including pathogens) to colo-
nize the lumen. This creates colonization resistance or non-
specific disease resistance in the gut, which increases resis-
tance to pathogens. A variety of potentially harmful organ-
isms are members of the normal gut microflora including 
bacteroides (some species are involved in putrefaction), clos-
tridia and Escherichia coli (potential pathogens). These or-
ganisms are probably not considered harmful as part of the 
native microbial community, as their pathogenic effects are 
kept under control by the normal equilibrium of gut micro-
bial metabolism. Disturbances in the normal intestinal mi-
crobial community structure can result in the proliferation of 
pathogens and cause gastrointestinal disorders [8]. Probiotic 
strains provide a number of benefits that have been reported 
or theorized. These benefits include: (1) re-establishment of 
balanced intestinal microflora and composition of intestinal 
flora, helping to increase the body’s ability to resist the inva-
sion of pathogens and maintain the host’s wellbeing; (2) im-
proving colonization resistance and/or prevention of diar-
rhea, urogenital diseases (Candida vaginitis), alleviation of 
constipation, protection against traveller’s diarrhea, preven-
tion of infantile diarrhea, reduction of antibody-induced diar-
rhea, control of inflammatory bowel diseases and irritable 
bowel syndrome; (3) systemic reduction of serum cholesterol 
confer health benefits to the cardiovascular system, including 
prevention and therapy of various ischemic heart syndromes; 
(4) reduction of fecal enzymes such as -glucuronidase,  
-glucosidase, nitroreductase and urease, potential mutagens 
which may induce tumors; (5) enhances lactose digestion 
and reduction of lactose intolerance; (6) enhancement of 
immune system response and prevent food allergy and atopic 
diseases; (7) improved calcium absorption; (8) synthesis of 
vitamins and pre-digestion of proteins. In addition, there 
have been reports of bacteriocins production by some probi-
otic bacteria, targeting pathogenic bacteria [8]. 
 Lactic acid bacteria and bifidobacteria, the most studied 
and widely employed bacteria within the probiotic field, are 
normal component of the intestinal microbiota and have a 
long tradition of safe application within the food industry 
[9]. They are usually added to fermented dairy products that 
represent about 56% of functional foods [8].  
 The definition of prebiotics was updated in 2004. They 
are defined as ‘‘selectively fermented ingredients that allow 
specific changes, both in the composition and/or activity in 
the gastrointestinal microbiota that confers benefits upon 
host wellbeing and health” [10]. These components resist the 
hydrolysis of the digestive enzymes, because specific link-
ages between monomers are resistant against breakage by
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Table 1. Main Functional Components of Foods and their Benefits 
Class/Component Potential Benefits 
Inulin, Fructo-oligosaccharides (FOS), 
Polydextrose 
Prebiotics: may improve gastrointestinal health; may improve calcium absorption 
Yeast, Lactobacilli, Bifidobacteria, and other 
specific strains of beneficial bacteria 
Probiotics: may improve gastrointestinal health and systemic immunity; benefits are strain-specific 
Dietary (functional and total) Fiber 
Insoluble fiber May contribute to maintenance of a healthy digestive tract; may reduce the risk of some types of cancer 
Beta glucan May reduce risk of coronary heart disease (CHD) 
Soluble fiber May reduce risk of CHD and some types of cancer 
Whole grains May reduce risk of CHD and some types of cancer; may contribute to maintenance of healthy blood 
glucose levels 
Flavonoids 
Anthocyanins-Cyanidin, Delphinidin, Malvidin Bolsters cellular antioxidant defenses; may contribute to maintenance of brain function 
Flavanols-Catechins, Epicatechins, Epigallo-
catechin, Procyanidins 
May contribute to maintenance of heart health 
Flavanones-Hesperetin, Naringenin Neutralize free radicals, which may damage cells; bolster cellular antioxidant defenses 
Flavonols-Quercetin, Kaempferol, Isorham-
netin, Myricetin 
Neutralize free radicals, which may damage cells; bolster cellular antioxidant defenses 
Proantocyanidins May contribute to maintenance of urinary tract health and heart health 
Carotenoids 
-carotene Neutralizes free radicals, which may damage cells; bolsters  cellular antioxidant defenses; can be made 
into vitamin A in the body 
Lutein, Zeaxanthin May contribute to maintenance of healthy vision 
Lycopene May contribute to maintenance of prostate health 
Isothiocyanates 
Sulforaphane May enhance detoxification of undesirable compounds; bolsters cellular antioxidant defenses 
Phenolic Acids 
Caffeic acid, Ferulic acid May bolster cellular antioxidant defenses; may contribute to maintenance of healthy vision and  
heart health 
Sulfides/Thiols 
Diallyl sulfide, Allyl methyl trisulfide May enhance detoxification of undesirable compounds; may contribute to maintenance of heart health 
and healthy immune function 
Dithiolthiones May enhance detoxification of undesirable compounds; may contribute to maintenance of healthy im-
mune function 
Plant Stanols/Sterols 
Free Stanols/Sterols May reduce risk of CHD 
Stanol/Sterol esters May reduce risk of CHD 
Phyto-estrogens 
Isoflavones-Daidzein, Genistein May contribute to maintenance of bone health, healthy brain and immune function; for women, may 
contribute to maintenance of menopausal health 
Lignans May contribute to maintenance of heart health and healthy immune function 
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(Table 1) contd…. 
Class/Component Potential Benefits 
Fatty Acids 
Monounsaturated fatty acids (MUFAs) May reduce risk of CHD 
Polyunsaturated fatty acids (PUFAs) 
-Omega-3 fatty acids-ALA 
May contribute to maintenance of heart health; may contribute to maintenance of mental and visual  
function 
PUFAs-Omega-3 fatty acids—DHA/EPA May reduce risk of CHD; may contribute to maintenance of mental and visual function 
Conjugated linoleic acid (CLA) May contribute to maintenance of desirable body composition and healthy immune function 
 
mammalian enzymes and are not absorbed in the upper part 
of the gastro-intestinal tract, indeed pass into the large intes-
tine where are located most of the indigenous intestinal  
microbiota. The presence of microbial enzymes able to act 
on these bonds allows these carbohydrates to be selectively 
degraded. Further selectivity is conferred by the fact that not 
all colonic microorganisms have the appropriate enzymes to 
degrade all linkages. The effect of a prebiotic is essentially 
indirect because the benefit to the host is mediated through 
selective stimulation of the growth and/or activity of one or a 
limited number of colonic bacteria, thus improving host 
health. It is not the prebiotic by itself but rather the changes 
induced in microflora composition that is responsible for its 
effects [11]. Bifidobacteria and/or lactobacilli are good target 
organisms [8].  
 A wide variety of dietary carbohydrates, especially 
fructo-oligosaccharide (FOS), galacto-oligosaccharides 
(GOS), inulin, isomalto-oligosaccharides (IMO), polydex-
trose, lactulose and resistant starch are considered as the 
main prebiotics components. These types of carbohydrates 
are not hydrolyzed by human digestive enzymes but are 
readily fermentable by specific colonic bacteria, such as bifi-
dobacteria and lactobacilli species, with the concomitant 
production of short-chain fatty acids. These acids, especially 
butyrate, acetate, and propionate, provide metabolic energy 
for the host and acidification of the bowel [12]. FOS are 
chain-like carbohydrates consisting of a chain formed of 
fructosyl units with a glucosyl at the end, or fructosyl chain 
alone. By the chain length, i.e. the number of fructosyl units, 
FOS are divided into oligo-fructoses having a shorter chain, 
of which 1-kestose and nystose can be given as examples, an 
inulin having a longer chain (a common designation for 
FOS, which may contain up to 60 fructosyl units). Many 
cultivated vegetables, such as sugar-beet, chicory, Jerusalem 
artichoke, asparagus, onion, garlic, banana and tomato, con-
tain FOS in abundance, however, FOS can also be produced 
synthetically. FOS are known to have a prebiotic effect, 
which means that they enhance selectively the growth of 
useful Bifidobacteria and Lactobacilli which produce acid in 
the intestines. FOS also reduce the pH in the intestines, thus 
inhibiting the growth of pathogen bacteria and maintaining 
optimal bacterial balance for human health. Other known 
effects of FOS on humans is an increase in excrements and a 
decrease in blood fat values and cholesterol level. Since di-
gestive enzymes such as -amylase, sucrase and maltase are 
not capable of decomposing FOS to any notable extent, and 
only the specific types of bacteria mentioned above utilize 
them selectively, FOS have been used as low-calorie sweet-
ening agents in food. However, owing to the prebiotic and 
other useful effects mentioned above, FOS have a potential 
of being used more extensively especially as a food supple-
ment to enhance intestinal activity. Inulin and oligofructose, 
non-digestible fermentable fructans, are amongst the most 
studied and well established prebiotics. These compounds 
have shown to increase calcium absorption, thus improve 
both bone mineral content and bone mineral density and  
reduce the risk of osteoporosis. Furthermore, delayed gastric 
emptying, modulation of gastro-intestinal transit times,  
improved glucose tolerance, reduced fat and cholesterol ab-
sorption via binding of bile acids, reduce the levels of cho-
lesterol and serum lipids, reduce the risk of cardiovascular 
disease associated with dyslipidemia, especially hyper-
triglyceridemia and inulin resistance. Increased volume and 
water carrying capacity of intestinal contents, reduce the 
constipation relief resulting from fecal bulking and possible 
effects on intestinal motility and suppression of diarrhea, 
especially when associated with intestinal infections [6]. The 
oligosaccharides play an important role in the obesity control 
through increased satiety and reduced hunger.  
 Bifidobacteria have a number of health promoting prop-
erties, such as improved intestinal environment and help to 
restore the normal flora after antibiotic therapy, inhibition of 
pathogenic bacteria, immunomodulation, synthesis of B  
vitamins, improved calcium absorption, lowered blood 
ammonia and cholesterol concentrations and inhibition of 
tumor formation [8]. Lactobacilli may aid digestion of 
lactose in lactose-intolerant individuals, reduce constipation 
and infantile diarrhea, help to resist infections such as sal-
monellae and help to relieve irritable bowel syndrome [11]. 
Prebiotics can be used in a wide range of food products: 
dairy foods, baked goods, cereals based foods and meat 
products.  
 Symbiotics have also been defined as mixtures of probi-
otics and prebiotics that beneficially affect the host by improv-
ing the survival and implantation of live microbial dietary 
supplements in its gastrointestinal tract. One of the main 
benefits of symbiotics is the increased persistence of probiot-
ics in the gastrointestinal tract [13]. 
2.1. Cereal 
 Cereals, in particular oat and barley, are functional food, 
being sources of non-digestible carbohydrates as lactulose, 
FOS, trans-GOS, that have been shown to be effective in 
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stimulating growth of bifidobacteria and lactobacilli in  
human large intestine.  
 Cereals contain water-soluble fibers, such as -glucan 
and arabinoxylan, that delay gastric emptying, reduce glu-
cose and sterol absorption by the intestine, decrease total and 
low density lipoprotein, serum cholesterol, and consequently 
reduce the risk of coronary heart disease, postprandial blood 
glucose, and insulin contents [12]. The potential cholesterol 
lowering of cereal fibers is considered to result from effects 
manifest in the upper gastrointestinal tract. These in turn 
may be related to the ability of cereal fibers to form a gel-
like network and alter gastrointestinal viscosity [14]. 
 Some functional cereal components were also applied  
in dairy, pasta and bakery industries. Recent research has 
focused on the use of -glucan in the manufacture of low-fat 
ice creams and yogurts. Incorporation of -glucan with their 
soluble dietary fiber into low-fat dairy products can make 
their mouth-feel, scoop-ability and sensory properties  
resemble those of full-fat products [9]. 
2.2. Legumes 
 Legumes and soya-derived foods contain isoflavones, 
often referred as phyto-estrogens. Genestein and daidzein are 
the main isoflavones. Isoflavones are heterocyclic phenols 
structurally similar to the estrogenic steroids. Because of 
they are weak estrogens, isoflavones may act as anti-
estrogens by competing with the naturally occurring endoge-
nous estrogens. This may explain why populations that con-
sume significant amounts of soya have reduced risk of estro-
gen-dependent diseases such as breast and prostate cancer. 
The consumption of foods rich in isoflavones may be associ-
ated with decrease risk of diseases. There is some evidence 
to suggest that isoflavones may be protective against hor-
mone dependent cancers and against age-related diseases 
such as cognitive-decline, cardiovascular disease and osteo-
porosis. Isoflavones are extensively metabolised in the gut 
(including action of the gut microflora) and liver. Although 
cholesterol lowering is one of the best documented cardio-
protective effects of soya, vascular protection may also con-
tribute to improve cardiovascular health and is likely to be 
mediated by isoflavones via a number of mechanisms includ-
ing effects on arterial function, cellular effects and estrogen-
receptor mediated effects. 
 The U.S. FDA has contributed to a considerable growth 
in the sales of soya foods in the US since the year 2000. The 
FDA approved the claim that soya protein included in a diet 
low in saturates and cholesterol may reduce the risk of coro-
nary heart disease by lowering blood cholesterol levels. The 
claim identifies 25g/day as the amount of soya protein  
required to produce health benefits. Currently, isoflavones 
are being used as bioactive ingredients in a wide range of 
functional foods from soya yogurts and puddings to tomato 
juice, containing soya germ. Indeed, a soya yogurt was de-
veloped using lactic acid bacteria and germinated soya bean 
extract that contains significantly higher levels of isofla-
vones, gamma-aminobutyric acid (GABA, the major inhibi-
tory neurotransmitter in the central nervous system) and free 
amino acids than conventional soya yogurts, and conse-
quently may have enhanced health benefits [15]. 
2.3. Fruit and Vegetables 
 The effects rendered by nutraceutical and functional 
foods are due to a cocktail of phytochemicals and bioactives 
present in fruit and vegetables. They are the principal source 
of such important nutrients as vitamins, minerals, folate, 
fiber, carotenoids, polyphenols, phytosterols. These com-
pounds are essential bioactive compounds with antioxidant 
protection on health. Free radicals have also been implicated 
in the development of neurodegenerative disorders such as 
Parkinson’s disease and Alzheimer’s disease, and in diabe-
tes, rheumatoid arthritis, and chronic obstructive pulmonary 
and other diseases. These diseases may, therefore, be benefi-
cially influenced by antioxidant consumption. The primary 
role of antioxidants in reducing the risk of cardiovascular 
disease is through inhibition of peroxidation in low density 
lipoprotein, although they may also influence other cardio-
vascular disease processes [16]. 
 Several epidemiological studies have shown that fruits 
and vegetables are protective against a variety of human can-
cers. Tomatoes have received much attention in recent years 
because of interest in lycopene, the primary carotenoid in 
this fruit, and its potential antioxidant role in cancer risk  
reduction. Garlic (Allium sativum) contains an odorless 
amino acid, which is converted enzymatically by allinase 
into allicin when the garlic cloves are crushed. Allicin then 
decomposes spontaneously to form numerous sulfur-
containing compounds (diallyl sulphide, diallyl disulfide), 
have been shown to inhibit tumor-genesis in several experi-
mental models. Epidemiological studies also suggested that 
allium vegetables, including onions, may confer a protective 
effect on cancers of the gastrointestinal tract. 
 The tea, particularly green tea, is rich in polyphenols. 
Catechins are the predominant and most significant of all tea 
polyphenols. Tea epigalocatechin gallate, an important tea 
constituent, has strong antioxidant, immuno-stimulatory, 
anti-inflammatory and antimicrobial activities. Human intake 
of green tea decreases total cholesterol, increases HDL frac-
tion and decreases lipoprotein oxidation [17]. Epidemiologi-
cal evidence has also associated the frequent consumption of 
cruciferous vegetables with decreased cancer risk. The anti-
carcinogenic properties of cruciferous vegetables have been 
attributed to their relatively high content of glucosinolates, a 
group of glycosides recordable in all cruciferous vegetables. 
Myrosinase, an enzyme found in plant cells, converts these 
compounds to a variety of hydrolysis products, including 
isothiocyanates, sulforaphane and indoles.  
 Several epidemiological studies have shown that citrus 
fruit are protective against a variety of human cancers.  
Although oranges, lemons, limes and grapefruits are a prin-
cipal source of such important nutrients as vitamin C, folate 
and fibre, Elegbede et al. [18] have suggested that another 
component is responsible for the anticancer activity. Citrus 
fruit are particularly high in a class of phytochemicals 
known as the limonoids. Evidence has been accumulating in 
support cancer-preventative effect of limonene [19].  
 Another important products category within the functional 
food segment is non-alcoholic beverages fortified with vita-
mins A, C and E or other ingredients, eye health drinks (with 
lutein) or bone health drinks (with calcium and inulin) [9]. 
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3. MAIN TECHNIQUES TO PRODUCE FUNCTIONAL 
FOOD  
 In the development of functional foods, it is essential to 
adopt an integrated approach which involves several interre-
lated elements functioning in harmony before the product 
can be successfully launched on the market. The process 
should start with considerations and decision-making about 
the product concept and positioning strategy, in particular 
with regard to regulatory positioning, labeling, etc. The next 
step is to identify chemically the bioactive components or 
ingredients which are considered to provide the desired 
beneficial effect on health. For example, modern liquid 
chromatography mass spectrometry analysis (LC/MS) can be 
applied for structural identification of target molecules. In 
the next step (product formulation), feasible technologies 
with appropriate analytical methods have to be applied or 
developed, if necessary, with the purpose of designing a 
product with the desired health-enhancing properties  
[20-22]. 
 Many technological challenges and possible solutions for 
functional foods are proposed for example to eliminate 
harmful component(s) or to increase the concentration of 
beneficial indigenous components. To this aim, it is possible 
to use enzymatic processes, membrane separation or super-
critical fluid extraction [23]. The last two techniques are also 
used for replacement of harmful components by beneficial 
components; whereas to increase bioavailability of beneficial 
components, microencapsulation technique may be adopted 
[24]. 
 Microencapsulation is a technology based on packaging 
solids, liquids or gaseous materials in miniature, sealed cap-
sules that can release their contents at controlled rate under 
the influences of specific conditions (Table 2). In a broad 
sense, microencapsulation can be used for many applications 
in food industry, including stabilizing the core material, con-
trolling the oxidative reaction, providing sustained or con-
trolled release, masking flavors, colors or odors, extending 
the shelf life and protecting components against loss [25].  
 Nanotechnology represents the most recent field with 
great potential in improving the efficiency of release of  
nutraceuticals and bioactive compounds in functional foods 
to improve human health [26]. Some of potential delivery 
systems based on nanotechnology are association colloids, 
nano-emulsions, nanostructured multiple emulsions, and 
also, nanocomposites, nanofibers and so on [27].  
 To improve retention of beneficial components in raw 
materials and foods encapsulation processes, pulsed electric 
field and sphere packaging have been also developed [23]. 
Such processes include the following aspects [28]:  
• Elimination of a component known or identified as caus-
ing deleterious health effects, e.g. allergenic proteins; 
• Increase of concentration of natural bioactive compo-
nent in the food, up to the desired effective level; 
• Addition of a component which is not normally present 
in most foods, but for which beneficial effects have been 
demonstrated; 
• Replacement of a component, usually a macronutrient, 
the intake of which is considered harmful to health in 
high intake amounts, by a component for which the 
beneficial effect has been demonstrated; 
• Improvement of the bioavailability or modification of 
food components for which beneficial effects have been 
demonstrated; 
• Monitoring amount and efficacy of beneficial bioactive 
components  
 The accurate identification of bioactive compounds is 
essential to identify relationships between different food 
components and health benefit. In addition, precise quantifi-
cation is critical to determine dietary intake levels and safety 
guidelines for potentially bioactive compounds necessary to 
achieve desired beneficial properties. Rapid analytical meth-
ods are needed to monitor the biomarkers influencing the 
disease state to effectively demonstrate benefits of this added 
value for consumers. The four common steps for any ana-
lytical method are sampling, sample preservation, sample 
preparation, and analysis (separation and detection) [29]. 
Over 90% of developments made during the past few dec-
ades has focused on the final step of analysis. Remarkable 
advances in instrumentation, spectroscopy, and chromatog-
raphy have resulted in rapid advancement of methods for 
high-throughput separation and detection of complex multi-
component mixtures containing trace quantities of the ana-
lytes of interest. The sampling is the collection of a represen-
tative sample from the entire matrix that needs to be ana-
lyzed. The sample is obtained in such a way that it truly rep-
resents the entire sample. Sample preservation is an impor-
Table 2. Techniques and Types of Materials for Encapsulating Probiotic Microorganisms 
Microencapsulation  Types of Materials for Coating  
Spray-drying  Water-soluble 
Spray-congealing  Waxes, fatty acids, water-soluble and water-insoluble polymers, monomers  
Fluidized-bed coating/ air-suspension  Water-insoluble and water-soluble polymers, lipids, waxes  
Extrusion  Water-soluble and water insoluble dehydrating liquid polymers  
Coacervation/phase separation technique  Water-soluble polymers  
Electrostatic method  Oppositely charged polymers/ Compounds  
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tant step as there is often some delay between sample collec-
tion and analysis. The proper sample preservation ensures 
that sample retains its physical and chemical characteristics 
from the time it is collected to the time it is analyzed [29]. 
Therefore, it is essential to inactivate all enzymatic, meta-
bolic, and chemical reactions during preservation to maintain 
accurate sample identity, and demonstrate the effectiveness 
of such procedures in any report. Thus, researchers need to 
study in detail the influence of storage temperature on the 
analyte of interest and preserve samples under appropriate 
conditions. Sample preparation consists of multiple steps 
such as sample drying, homogenization, sieving, extraction, 
pre-concentration, derivatization, and hydrolysis. The motive 
behind sample preparation can be multi-fold: to increase the 
efficiency of an assay procedure, to eliminate or reduce po-
tential interferences, to enhance the sensitivity of the analyti-
cal procedure by increasing the concentration of the analyte 
in the assay mixture, and sometimes to convert the analyte of 
interest to a more suitable form that can be easily separated, 
detected, and/or quantified [30]. Once the sample preparation 
is completed, the analysis is carried out by selected instru-
ments. A variety of instruments are used for different types 
of analysis, depending on the information to be acquired. 
There is seldom a unique way to design a measurement 
process. Even an explicitly defined analysis can be  
approached in more than one ways. The objective of an ana-
lytical measurement can be qualitative or/and quantitative 
[29]. 
4. RECENT TEST-PATENTS 
4.1. Diabetes Preventing 
 The document EP1920774A1 describes the composition 
for treating cancer, viral infection, allergic disease, autoim-
mune disease, inflammatory diseases or diabetes [31]. This 
invention relates compositions based on fucoidan or a fu-
coidan hydrolysate and an immuno-stimulating material that 
can be used in foods, beverages, pharmaceutical, health 
foods, functional foods and cosmetics. It also helps to reduce 
the time taken to select lactic acid bacteria that have a strong 
immuno-stimulating activity. To this aim, fucoidan or a 
product obtained by acid hydrolyzing fucoidan is used in 
combination with an immuno-stimulating material. This 
combination synergistically potentiates the immuno-
modulatory or immuno-stimulating activities of the ingredi-
ents. The immuno-modulatory activity as used herein does 
not mean indirect regulation of immuno-function through 
improvement of enterobacteria, as achieved by xylo-
oligosaccharides, but means direct activation of immuno-
competent cells as exhibited by several kinds of fucoidan.  
 Another objective of the present invention is to provide a 
composition, an effective amount of which can be added in a 
precise manner to foods/beverages or pharmaceuticals. Fu-
coidan or a hydrolysate and the immuno-stimulating material 
that are combined in accordance with the present invention 
offer the advantage of exhibiting an enhanced immuno-
modulatory or immuno-stimulating action, compared with 
their individual application. This makes it possible to de-
velop foods, beverages and pharmaceuticals that are more 
effective than products that incorporate the conventional 
immuno-stimulating materials. Such high efficacy contrib-
utes to a reduction of the amount of immuno-stimulating 
material to be added. These advantages bear particular im-
portance when lactic acid bacteria are used as immuno-
stimulating material. For instance, lactic acid bacteria of low 
water solubility may be prevented from precipitating if the 
amount of their inclusion is reduced. In addition, the step of 
selecting lactic acid bacteria that have both immuno-
stimulating activity and desired fermentation characteristics 
can be skipped. As Fucoidan or its hydrolysate is isolated 
from a natural foodstuff, its effect is mild but with a very 
high degree of safety. Fucoidan derived oligosaccharides 
have low molecular weights, so they are easy to handle and 
can be manufactured in a simple manner; in addition, be-
cause of their high safety, such oligosaccharides may be 
combined with immuno-stimulating materials to prepare 
functional formulations.  
 The document US7618951B2 has as an object of inven-
tion the development of food containing prebiotics, prefera-
bly gluco-oligosaccharides, or pharmaceutical compositions 
for preventing onset of type II diabetes mellitus in predis-
posed patients [32]. The invention relates to the use of prebi-
otics for the preparation of food or pharmaceutical composi-
tions which are intended for the treatment and/or prevention 
of hyper-glycemic syndromes and, in particular, for the 
treatment of Type II diabetes and/or the prevention of the 
onset of Type II diabetes in patients with a predisposition to 
developing diabetes. The invention also relates to the food 
and pharmaceutical compositions containing the prebiotics. 
Prebiotics are non-digestible dietary compounds broken 
down by the microorganisms of the intestinal flora and 
whose breakdown is responsible for certain health benefits. 
These beneficial health effects are due to a selective stimula-
tion of the growth and/or the biological activity of certain 
microorganisms of the intestinal flora, in particular the bifi-
dobacteria and the lactic acid bacteria of the colic flora. The 
effects of prebiotics are principally due to stimulation of the 
growth of bifidobacteria (bifidogenic effect). The stimulation 
of this growth allows a reduction in the pH of the colon, an 
increase in the production of short chain fatty acids, in par-
ticular butyrate and propionate, a prevention of the installa-
tion of pathogenic microorganisms (barrier effect), an  
increase in the metabolization of potentially carcinogenic 
compounds and the production of vitamin B. The use of pre-
biotics also allows stimulation of the immuno-system due to 
the production of lipoteichoic acid by the bacteria, the inter-
action of these bacteria with the Peyer' s patches and the 
stimulation of peripheral lymphocyte circulation. Prebiotics 
also encourage the digestive absorption of minerals, in par-
ticular calcium and magnesium, which allow their potential 
application in the context of the treatment of osteoporosis. In 
the conditions under study the prebiotics that are clearly  
defined are sugars classed among dietary fibers: non-
digestible oligosaccharides (also called oligosides). Oligo-
saccharides are monosaccharide polymers with a low degree 
of polymerization. The number of osidic units is typically 
from 2 to 12 units with an average of approximately 3-5 
units. The monosaccharides involved in the formation of 
oligosaccharides are varied, in particular hexoligosides such 
as glucose, galactose, and fructose, but also pentoligosides 
such as xylose are found. Oligosaccharides can be derived 
from the breakdown of natural polymers, such as starch or 
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insulin, by direct extractions from natural substances, such as 
soybean, or by chemical or enzymatic syntheses. Gluco-
oligosaccharides (GOS) constitute an important class of oli-
gosaccharides. The present invention also demonstrates that 
the glycemia of mice suffering from type II diabetes could be 
reduced through a treatment based on prebiotics. Thus, the 
principal aim of the invention is to provide functional food, 
nutraceuticals or medicaments, intended for the treatment 
and/or the prevention of hyperglycemic syndromes and in 
particular for the treatment of type II diabetes and/or the pre-
vention of the appearance of type II diabetes in at-risk sub-
jects. An aspect of the invention is also food composition, 
nutritional additives, functional food, or nutraceuticals, com-
prising one or more prebiotics, intended for the nourishment 
of subjects suffering from hyperglycemic syndrome and/or at 
risk of developing this syndrome. The invention also relates 
to any pharmaceutical composition that is characterized by 
one or more prebiotics in combination with a pharmaceuti-
cally acceptable vehicle. The tests carried out by the inven-
tors showed that the excess weight of the control and treated 
animals were similar and the fatty deposits were equivalent. 
Moreover the glicosuria and the fasting glycemia were nor-
mal, thus indicating no signs of obesity-related diabetes. The 
glucose tolerance test by contrast indicated that the control 
mice presented a glucose resistance while this phenomenon 
was significantly corrected in the treated mice. Glucose in-
tolerance is considered to be one of the first symptoms of the 
appearance of type II diabetes. It therefore appeared that the 
treatment with gluco-oligosaccharides was sufficient to pre-
vent the appearance of this diabetes in a murine obesity 
model. 
 The document US7422764B2 describes an edible liquid 
composition for treating or preventing disease or disorder, 
e.g. overweight and diabetes type II in mammal [33]. It 
comprises pectin and alginate, calcium, and indigestible oli-
gosaccharide. The edible liquid composition based on pectin, 
calcium and indigestible oligosaccharide needs proper char-
acteristics in terms of pH, viscosity, temperature and shear 
rate. Another aspect of the invention relates a method for the 
treatment or prevention of overweight or obesity in mam-
mals. Obesity is a major health problem; approximately 
ninety-seven million people are considered clinically over-
weight in the United States. Various chemical approaches 
have been proposed for controlling obesity. Anorectic agents 
such as dextroamphetamine, the combination of the non-
amphetamine drugs phentermine and fenfluramine (Phen-
Fen), and dexfenliuramine (Redux) alone, are associated 
with serious side effects. Indigestible materials such as 
olestra, mineral oil or neopentvl esters have been proposed 
as substitutes for dietary fat. Garcinia acid and derivates 
thereof have been described as treating obesity by interfering 
with fatty acid synthesis. Surgical techniques such as tempo-
rary ilcal bypass surgery are employed in extreme cases. 
However, methods for treating obesity, such as those de-
scribed above have serious shortcomings. Controlling the 
diet remains the most prevalent technique for controlling 
obesity. Hence, new compositions suitable for the treatment 
of obesity are highly desired. The accumulation or mainte-
nance of body fat bears a direct relationship to caloric intake. 
Therefore, one of the most common methods for weight con-
trol to combat obesity is the use of relatively low-fat, high 
fiber food. Especially high viscosity fibers may advanta-
geously be employed in anti-obesity diets. The high viscosity 
fibers may induce a sensation of satiety when ingested in a 
sufficient amount. The present invention relates to a compo-
sition that is liquid at around neutral pH and forms a viscous 
matrix at low pH. The composition comprised pectin, cal-
cium and oligosaccharides and is particularly suitable for use 
in a method of treating or preventing overweight or obesity. 
Thus, the present invention also encompasses the method of 
treating overweight or obesity in mammals, by the intake of 
an effective amount of the aforementioned composition. Cal-
cium is essential in the diet. Calcium deficiency may result 
in the following symptoms: muscle cramps, brittle nails, ec-
zema, aching joints, increased cholesterol levels, rheumatoid 
arthritis, tooth decay and numbness in the arms and/or legs. 
Additionally, it is of importance in compositions, which are 
used to prevent or treat overweight and obesity. It has been 
described that calcium contributes to the prevention of obe-
sity when absorbed by the body. Consequently, there are 
severe limitations to the use of low methoxylated pectins in 
compositions designed to reduce body weight and/ or to pre-
vent body weight increase due to the impact of pectin and/or 
alginate on the bioavailability of calcium. The ingestion of 
nutritional compositions, including those that are designed to 
prevent or treat excessive body weight, should not become 
an undue burden. Humans participating in a weight control 
program including a specific diet often prematurely discon-
tinue the program due to the adverse taste, insufficient palat-
ability or difficulty of consuming the dietary components. 
The inventors experienced that compositions in liquid form, 
are preferred by subjects participating in a weight control 
program. It is therefore a prerequisite that a composition 
designed to reduce body weight or control the caloric intake 
is provided in a liquid form, with limited viscosity. However, 
this provides an additional challenge, since calcium and low 
methoxylated pectins form a viscous mass when present in 
an aqueous environment. It was found by the inventors that 
the calcium absorption inhibitory effect of low methoxylated 
pectins and/or alginate present in edible liquid composition 
can be decreased effectively through the co-administration of 
calcium and indigestible oligosaccharides with a degree of 
polymerisation between 2 and 60. The present liquid edible 
composition uses a calcium salt that provides only limited 
amounts of free calcium ions at around neutral pH and an 
increased amount of free calcium ions at acidic pH. The pre-
sent composition thus provides a composition which is easy 
to consume, which induces feelings of satiety after ingestion 
and which ensures sufficient calcium bioavailability. A con-
sumer may easily prepare the present edible liquid composi-
tion from e.g. a powder that contains pectin and/or alginate, 
calcium and oligosaccharide by simply adding a predeter-
mined amount of water and/or milk. The suitable solvent 
preferably has a pH above 6 and may properly be selected 
from the group consisting of water, milk and mixtures 
thereof. Preferably, the mixture for making the present edible 
liquid composition is in the powder form. The invention also 
provides a process for preparing the liquid composition, 
comprising admixing the aforementioned mixture with a 
solvent that is preferably selected from the group consisting 
of water, milk and mixtures thereof. The term "reconsti-
tutable form" as used herein refers to a preparation that needs 
addition of a suitable liquid (preferably water) to obtain the 
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present edible liquid composition. Preferably the "reconsti-
tutable preparation" is a powder. The present composition 
may also be in a ready to drink form, and can be consumed 
without further preparation, i.e. does not require the addition 
of water before ingestion. The specific combination of the 
ingredients of the present composition also ensures a good 
shelf life. 
 The document US20100285156A1 has as an object of 
invention the development of functional food for improving 
or alleviating metabolic diseases e.g. diabetes, hyperlipide-
mia, arteriosclerosis, cardiovascular diseases and/or fatty 
liver, comprises extract of Lysimachiae foenumgraeci herb 
[34]. Disclosed are raw material, functional foods, and herb 
medicines for preventing and treating metabolic diseases, 
which comprises a Lysimachiae Foenum-Graeci herb extract 
as an effective ingredient. The extract is able to reduce blood 
glucose levels, triglycerides and cholesterol levels, AST 
(Aspartate Aminotransferase – Liver Function Tissue Dam-
age) and ALT (Alanine aminotransferase – Liver Function 
Cell Damage) levels, and fat in the liver, and thus can be 
effectively used as a hepatic protector and a remedy for pre-
venting and treating various metabolic diseases including 
diabetes, high blood pressure, fatty liver, cardiovascular dis-
eases, and hyperlipidemia. 
 The patent US20100144668A1 mentions semi-fluid 
foodstuff comprising guar gum and -glucan fibers per por-
tion of foodstuff, useful to prevent diabetes, obesity, and 
cardiovascular disease, to reduce postprandial insulinemia 
and as functional food [35]. The invention also relates to 
novel food products including dietary fibers (guar gum and 
-glucan fibers) intended to decrease the insulinaemia re-
sponse. The ingestion of a typical meal, supplying proteins, 
lipids and carbohydrates, is quickly followed by an increase 
in glycaemia due to the absorption of carbohydrates. Glucose 
and fatty acids (FAs) are the body's two principal sources of 
energy and their uses are interconnected. Their respective 
degree of use is determined by insulin. The intensity of the 
oxidation of FAs is determined by their concentration in the 
blood and that of glucose would follow the same law in the 
absence of insulin. The balance between carbohydrate oxida-
tion and lipid oxidation is thus achieved on the basis of sim-
ple competition for substrates, taking into account that the 
use of glucose is given priority by insulin, which induces its 
secretion [36]. The situation immediately postprandial (the 
first two hours after a meal) is a combination of hyper-
glycaemia and the hyper-insulinaemia it causes. A conse-
quence of this hormonal change is a stimulation of the use of 
glucose by insulin-sensitive tissues, principally by an in-
crease in glucose transport in cells. In addition, any rise in 
the concentration of insulin in the blood corresponds to a 
drop in the concentration of circulating FAs. Indeed, insulin 
inhibits the mobilization of stored lipids and favors their 
storage in fat tissues [37, 38]. Current consumption habits 
supply a higher quantity of energy than the quantity of en-
ergy expended daily. The body, due to higher insulin secre-
tion, stores this surplus energy. Therefore, to remediate this 
situation, the consumption of energy beyond daily energy 
requirements must be limited. One needs to decrease the fat 
content of food, as well as to reduce insulin secretion by 
modifying the supply of carbohydrates in such a way that 
they cause less insulin secretion. The inventors aimed to 
identify ingredients to decrease the insulinaemia response of 
a meal in subjects, in particular healthy subjects of normal 
weight or overweight subjects (20<BMI<30) while maintain-
ing a relatively low glycaemic response. Numerous studies 
on the impact of soluble dietary fibers were carried out. 
Studies of note include those of Spiller et al. [39] that de-
scribed the hypolipidaemia effect of fibers of guar gum or of 
3-glucan and the effect of guar gum and oat fibers source on 
plasma lipoproteins and cholesterol in hyper-cholesterolemic 
adults [39]; the study of Begin et al. [40] which described 
the effect of soluble dietary fibers (guar gum, carboxymeth-
ylcellulose, mustard mucilage, or oats) on glycaemia and 
insulinaemia; the study of Vachon et al. [41], which de-
scribes that soluble dietary fibers have a positive effect on 
postprandial insulinaemia but little effect on glycaemia.  
 The document WO2010098609A2 describes the pharma-
ceutical composition useful for prevention and treatment of 
diabetes mellitus comprises shikonin compound as an active 
ingredient, carrier, and additive or excipient [42]. The  
present invention relates to a composition comprising 
shikonin compounds, especially, isobutyryl shikonin, --
dimethylacryl shikonin, isovaleryl shikonin, and -methyl-n-
butyryl shikonin as active ingredients for prevention and 
treatment of diabetes mellitus. The composition of the pre-
sent invention showed stimulating effect on the release of 
insulin in the beta cell of the pancreas due to inhibitory ef-
fect on K-ATP ion channel of beta cell in pancreas together 
with promoting effect on the increase of calcium concentra-
tion. Therefore, it can be used as the therapeutics, health 
functional food or food additive for treating and preventing 
diabetes mellitus. 
 The document US7772212B2 describes the useful com-
position for decreasing population of pathogenic bacteria e.g. 
Escherichia coli in bird's intestine, comprising commercial 
avian food and at least one maltosyl-isomalto-
oligosaccharide with specific linkages at specific concentra-
tion of IMO to inhibit avian pathogenic intestinal bacteria 
[43]. IMO produced by Leuconostoc mesenteroides ATCC 
13146 fermentation with a sucrose:maltose ratio of 2:1 have 
been discovered to be effective prebiotics in mixed cultures 
of microbial populations. Surprisingly, in mixed microbial 
cultures this IMO composition proved to be effective as 
FOS. Thus, it can be used as effective prebiotic formulation 
for both birds and mammals. Moreover, the IMO were dis-
covered to be effective non-competitive inhibitors of  
-glucosidase, thus becoming useful in a therapeutic applica-
tion for several diseases, including obesity, diabetes mellitus, 
pre-diabetes, gastritis, gastric ulcer, duodenal ulcer, caries, 
cancer, viral disease such as hepatitis B and C, HIV, and 
AIDS. A diet with 5-20% IMO was also shown to reduce the 
abdominal fat tissue in mammals. This invention pertains the 
use of maltosyl-IMO as a dietary supplement specifically for 
birds and mammals to promote the growth of beneficial in-
testinal microbes, inhibit the growth of pathogenic intestinal 
microbes, and for therapeutic intervention during diseases 
such as diabetes. As previously stated, prebiotics are non-
digestible food ingredients that selectively stimulate the 
growth and/or activity of beneficial microbial strains (probi-
otics) residing in the host intestine [44]. It is believed the 
ability of these probiotics to catabolize oligosaccharides (two 
to ten monosaccharide units linked with glycosidic bonds), 
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to bestow beneficial health effects. Certain oligosaccharides 
are used as prebiotics. They are resistant to metabolism and 
adsorption in the small intestine and positively influence the 
composition of microflora in the large intestine. Oligosac-
charides used as prebiotics are currently produced either by 
extraction from plant sources, acid or enzymatic hydrolysis 
of polysaccharides or enzymatic synthesis by transglycosyla-
tion reactions. They are composed of a D-glucopyranose unit 
at the non-reducing end (G) linked via an -1,2 linkage  
to two or more 13-2,1-linked fructosyl units (F). This  
group includes 1-kestose (GF2), nystose (GF3), and 1  
F-fructofuranosyl nystose (GF4). Many of the oligosaccha-
rides marketed commercially are FOS, e.g., Raftilose and 
Nutraflora in the United States. GOS, which are -galactosyl 
derivatives of sucrose, are present in many legume seeds. 
Mono-, di-, and tri--galactosylsucrose, known respectively 
as raffinose, stachyose, and verbascose, are produced by 
extraction from plants, particularly soybeans. These oligo-
saccharides are known to be, in part, responsible for the 
flatulence and diarrhea that follows consumption of beans, 
because of the absence of -galactosidase in the gastrointes-
tinal tracts of humans and animals. Gluco-oligosaccharide 
(GOS) is a generic term for poly-glucose oligomers. GOS 
may contain a number of different linkages and are generally 
obtained from starch hydrolysates (maltose and maltodex-
trins) through the action of the -transglucosidase  
(EC 2.4.1.24) from Aspergillus spp. Gluco-oligosaccharides 
can also be produced by restricting polymer size during the 
fermentation process. A subcategory of GOS is the IMO, 
which contain -1.6 bonds in their main chain. Ingested oli-
gosaccharides (prebiotics) are capable of reaching the colon 
without being digested. It has been proposed that Lactoba-
cilli and Bifidobacteria, which are considered beneficial spe-
cies of the human intestinal tract, preferentially utilize FOS. 
Substituting FOS as a carbon source would preferentially 
increase the concentration of Lactobacillus and Bifidobacte-
ria species with a concomitant rise in the intestinal produc-
tion of lactic acid and short-chain fatty acids (SOFA). Both 
these products would have the net effect of lowering the pH 
in the large intestine. FOS, GOS, and soy-bean oligosaccha-
rides were found not to be digested by enzymes secreted by 
small intestine, but to be fermented by certain microorgan-
isms found in human and livestock intestines, especially by 
the Bifidobacterirum spp. Starch is one of the most readily 
available fermentable sources of energy for organisms and 
makes up 60-70% of the dietary carbohydrate consumption 
in humans. Humans secrete a pancreatic -amylase that 
cleaves starch to a di-(maltose), tri-(maltotriose), and 
branched -dextrins in the duodenal cavity. As there is no 
integral transport process in the intestinal enterocyte that can 
accommodate anything larger than free glucose, these oligo-
saccharides are further processed to glucose in the intestinal 
surface membrane by -glucosyl saccharidases, including -
glucosidase. These enzymes form part of a large glycopro-
tein component of the intestinal surface brush border mem-
brane. Once formed, glucose then may be co-transported into 
the enterocyte. Inhibitors of -glucosidase are known to de-
lay the digestion of starch, of starch-derived oligosaccha-
rides, and sucrose (U.S. Pat. Nos. 5,840,705; and 4,013,510; 
and U.S. Patent Application No. 200410081711). At least 
two commercial oral -glucosidase inhibitors, miglitol and 
acarbose, are currently prescribed for use in managing no-
insulin-dependent diabetes mellitus by slowing the appear-
ance of glucose in the blood after eating.  
4.2. Anti-Obesity 
 The document WO2010064845A2 describes the compo-
sition useful for preventing and treating obesity, hyperten-
sion, and hyperlipidemia, based on Myristica fragrans Hout-
tuyn extract [45]. The extract may be used for the prevention 
and treatment of obesity caused by the intake of high-fat 
diets, the increase in weight of periovarian fats and the ac-
cumulation of abdominal fats caused by the hypertrophy of 
adipocytes (fat cells).  
 The document US7790702 mentions protein/ phosphol-
ipid bonded substances that improve lipid and cholesterol 
metabolism for treatment of hypertension, obesity, fatty liver 
etc [46]. The present invention relates to a protein/ phosphol-
ipid or protein hydrolyzate/phospholipid complex containing 
10 wt % or more of bound phospholipid, a lipid metabolism 
improving agent and a functional food comprising the com-
plex. 
 The document WO2010104242A1 discloses new modi-
fied Lactobacillus FARM1, FARM2 and FARM3 strains, 
useful in pharmaceutical composition and functional food for 
preventing and treating obesity and metabolic diseases in-
duced by obesity [47]. The present invention relates to pre-
vention and treatment of obesity and metabolic diseases in-
duced by obesity, particularly for the prevention and treat-
ment of obesity by improving the characteristics of intestinal 
bacteria. In the present invention, it was ascertained that the 
characteristics of intestinal bacteria are transformed by the 
intake of a microbial preparation that reduces free fatty acid 
absorption in the gastrointestinal tract. A modified Lactoba-
cillus strain usable for such purposes is provided. The pre-
sent invention shows a weight loss effect equal to that of 
orlistat that is the most widely used anti-obesity therapeutic 
agent.  
 The document WO2010013978A3 describes the compo-
sition to prevent or treat hyperlipidemia, fatty liver, cardio-
vascular disease or obesity, comprises sialic acid compounds 
[48]. The invention relates to a composition for the preven-
tion or treatment of hyperlipidemia, fatty liver, cardiovascu-
lar disease, or obesity, which includes a compound expressed 
by the following general formula I as its active ingredient:  
 General formula [I]: S-(MS)p-(MS)q where S represents 
sialic acid, and (MS)p and (MS)q monosaccharide residue, 
respectively.  
 The compound used as active ingredient causes weight 
loss, reduces organ fat, reduces total cholesterol concentra-
tion, reduces LDL cholesterol value, and reduces leptin 
value, thus exhibiting positive activity in prevention or 
treatment of hyperlipidemia, fatty liver, cardiovascular dis-
eases, or obesity. In addition, because the composition of the 
present invention is free of cytotoxicity and skin adverse 
reactions, it may safely be applied in pharmaceutical and 
functional food compositions. 
 The document US20100151057A1 describes a pharma-
ceutical compound for use as raw material, functional food, 
cosmetic or crude drug for preventing and treating obesity, 
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based on extract of Lysimachiae Foenum-graecum herb [49]. 
An anti-obesity active extract obtained from a medicinal 
plant was disclosed. The extract can suppress the adipocyte 
differentiation and decreases body weight and body fat in an 
obese animal, thereby suppressing fat accumulation. Obesity 
is a disease caused by a metabolic error, in which excessive 
energy in a body is converted into fat and the fat is exces-
sively accumulated in adipose tissue, thereby abnormally 
increasing body fat. Factors causing obesity are largely di-
vided into genetic factors and environmental factors. The 
present invention provides a raw material, a functional food, 
cosmetic, a crude drug, etc. for an obesity preventing or 
therapeutic agent, in which the extract having a significant 
effect on suppression of adipocyte differentiation and a  
decrease in body weight and body fat in an obese animal 
model is included as an active ingredient. The invention also 
provides the method of extracting the extract from the Lysi-
machiae Foenum-graecum herb. The method included the 
following steps: (1) drying and grinding the herb; (2) carry-
ing out solvent extraction by adding an organic solvent in an 
amount of 5 to 50 times by weight of the herb obtained in the 
first step; and (3) filtering extract solution of the organic 
solvent by using a filter paper, and carrying out vacuum con-
centration at temperature of 40°C or less. The composition 
according to the present invention includes the extract in an 
amount ranging from 0.1 to 50%, based on the total weight 
of the composition. The composition may additionally in-
clude a carrier, an excipient, or a diluent. A solid preparation 
for oral administration includes tablet, pill, powder, granule, 
capsule, etc., and such a solid preparation may be prepared 
by mixing the extract with at least one excipient (such as 
starch, calcium carbonate, sucrose, lactose, gelatin, etc). 
Also, in addition to the excipient, lubricants, such as magne-
sium stearate, and talc, may be used. A liquid preparation for 
oral administration includes suspension, liquid for internal 
use, emulsion, syrup, etc., and in addition to a frequently 
used main diluent, such as water and liquid paraffin, the 
preparation may include a variety of excipients (for example, 
a wetting agent, a sweetening agent, an aromatic agent, a 
preservative, etc). A formulation for parenteral administra-
tion includes a sterile aqueous solution, a non-aqueous sol-
vent, a suspension, an emulsion, a freeze-dried preparation, 
and a suppository. The current patent also provides a health 
care food for preventing an anxiety disorder related to a cra-
nial nerve system, which includes the Lysimachiae Foenum-
graecum herb extract and an acceptable food supplement 
additive. It may be added to various foods and may be used 
in the form of pills, powders, granules, infusion, tablets, cap-
sules, or drinks. The food supplement additive defined in the 
present specification includes food additives conventionally 
known as fragrance agents, flavoring agents, coloring agents, 
fillers, stabilizers, etc. Besides the extract as essential ingre-
dient in a predetermined quantity, the health drink composi-
tion may include other ingredients without particular limita-
tions, and may include various fragrance agents, natural 
starch, various nutrients, vitamins, minerals, flavor agents, 
coloring agents, extenders (cheese, chocolate, etc.), pectic 
acid and salt thereof, alginic acid and salt thereof, organic 
acid, protective colloid thickeners, pH adjuster, stabilizer, 
preservatives, glycerin, alcohol, and carbonating agents. 
 The document US7704979 also reports the method for 
treating, reducing or attenuating obesity [50]. The current 
invention provides methods of inducing the loss of adipose 
tissue by providing a diet high in calcium. In one aspect of 
the invention, the calcium is provided in the form of dairy 
products. In yet another aspect of the invention, calcium is 
provided in the form of a dietary supplement, such as cal-
cium carbonate of vitamin supplements. Methods of sup-
pressing [Ca
2+
]i levels in individuals are also provided. The 
invention also provides methods of stimulating lipolysis, 
inhibiting lipogenesis, and increasing the expression of white 
adipose tissue uncoupling protein 2. Moreover, it also pro-
vides methods of increasing the core temperature of an indi-
vidual. The regulation of body weight, and particularly body 
fat in animals, is a complex process having enormous impli-
cations for the health and wellbeing of humans and other 
animals. Excess body weight and/or excess of body fat rela-
tive to lean body mass have been associated with a wide 
range of health problems including coronary artery diseases, 
stroke, and diabetes. It has been estimated that half of all 
American people are over-weight. Within the United States 
about 24% of men and 27% of women are defined as mildly 
to severely obese. Individuals 20% over ideal weight guide-
lines are considered obese. Obesity is classified as mild  
(20-40% overweight), moderate (41-100% overweight), and 
severe (>100%) overweight. Severe obesity is relatively rare, 
affecting less than 0.5% of all obese individuals and about 
0.1% of the total population. Obesity is not just a problem 
for humans. Therefore, it is critical to maintain a healthy 
weight in order to minimize disease risk (U.S. Pat. No. 
6,071,544). Obesity in humans is treated by a variety of 
means ranging from surgical procedures (gastric bypass) for 
the severely obese to diet therapy, behavior modification, 
and medication for the mildly to moderately obese. Man-
agement of moderate and mild obesity is typically performed 
by the individual and commercial organizations that provide 
behavior modification programs and, in some cases, pre-
packaged diets. The medical community recommends that 
diet treatments should be administered under medical super-
vision. The range of treatments for obesity reflects the com-
plexity of the processes involved in weight regulation and 
the current lack of understanding of these processes. Recent 
reports have even implicated viruses as a possible causative 
factor in obesity (U.S. News and World Report, Aug. 7, 
2000). There are also numerous reports of possible genetic 
bases for a predisposition to obesity. The present invention 
also provides methods for attenuating weight and adiposity 
in children and for inducing the loss of adipose tissue in hu-
mans or other animals by increasing the amounts of dietary 
calcium. Novel and advantageous methods of restoring nor-
mal body fat ratios in women post partum are also provided. 
This is put in practice by identifying an individual who has 
recently given birth to a child and increasing the amount of 
dietary calcium consumed by the individual. Methods of 
preventing or reducing the regain of weight lost after an ini-
tial period of dieting are also provided by the current inven-
tion. Methods of reducing, treating, or attenuating obesity in 
an individual comprising the administration of therapeuti-
cally effective amounts of 1,25-(OH)2-D receptor antagonists 
are also suggested. Calcium provided to an individual in ac-
cordance with the subject invention may take the form of, for 
example, a dairy product (for example milk, no-fat dry milk, 
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yogurt, cheese, cottage cheese, ice cream or frozen yogurt), a 
nutrient supplement (such as calcium fortified vitamins and 
liquids supplemented with calcium), foodstuffs supple-
mented with calcium, or other foods high in calcium (for 
example, salmon, beans, tofu, spinach, turnip greens, kale, 
broccoli, waffles, pancakes, or pizza). Recommendations 
regarding increases in the amount of calcium consumed by 
the individual, as well as sources of dietary calcium, may be 
provided from a database that compares the amount of cal-
cium consumed with that found to optimize or induce weight 
loss. The weight/height ratio may be calculated by obtaining 
the weight of an individual in kilograms and dividing this 
value by the height of the individual in meters. Alternatively, 
the weight/height ratio may also be calculated by multiplying 
the weight of the individual in pounds (lbs) by 703 and di-
viding this value by the square of the height of the individual 





. Information  
related to the benefits of maintaining a normal weight, or 
optionally a normal weight/height ratio, dietary plans con-
taining high levels of calcium and printed matter disclosing 
the benefits of a high calcium diet may, optionally be pro-
vided in electronic or printed form and may be stored in a 
database. A further aspect of this invention is the method for 
promoting good health by providing a product with calcium 
accompanied by information regarding the benefits of the 
consumption of calcium with respect to the control of obe-
sity. The information regarding the benefits of the consump-
tion of calcium would typically include, for example, a writ-
ten or verbal explanation that the consumption of calcium is 
associated with weight loss and/or the prevention of weight 
gain. This information can be presented in such a way so that 
a potential purchaser and/or user of a product which contains 
calcium would understand that the consumption of the prod-
uct with calcium could cause weight loss or reduce weight 
gain, and that the weight loss or reduction in weight gain 
from the use of the product would be directly attributable, at 
least in part, to the calcium present in the product. In a pre-
ferred embodiment, the provider of a particular calcium-
containing product communicates the obesity control bene-
fits of calcium. The obesity-control information provided 
according to the subject invention maybe provided with, or 
without, information relating to other health benefits that 
may be attributed to calcium or other components of the 
product, which contains calcium. In a specific embodiment, 
information regarding calcium obesity-control benefits 
would be practiced by a commercial entity having a financial 
interest in the sale of a product, or a class of products, which 
contain calcium.  
 The document EP2168445A1 reports the method for  
obtaining a dietary fiber composition useful to produce func-
tional food products as pasta, bakery products, breakfast  
cereals, snack or drink [51]. The method for treatment of 
bran to obtain a dietary fiber composition comprises the step 
of subjecting the bran to solubilization in the presence of an 
enzymatic mixture obtained from a culture of a Trichoderma 
strain, the culture being incubated on substrate containing at 
least 1% (w/v) of bran in conditions suitable for the produc-
tion of lytic enzymes. It is also described a dietary fiber 
composition having prebiotic properties which contains a 
quantity of soluble fiber greater than about 2% by weight 
over the total dry weight of fibres and a polyphenols level 
accounting about to 0.15 mg of gallic acid per 100 g of fibers 
according to the Folin-Ciocalteus method. The present in-
vention further refers to a dietary fiber composition having 
an increased soluble fiber content and its use in the prepara-
tion of high soluble fiber functional food with prebiotic 
properties. Such a problem has to be solved, according to the 
invention. According to an embodiment of the present inven-
tion, the bran present in the substrate is the same as the bran 
subjected to solubilization. Preferably, the Trichoderma 
strain is chosen between T. reesei strain 67 and T. harzianum 
strain T22. The bran preferably consists of durum wheat 
bran, chosen from the cereal processing by-products referred 
to as B&B50 and B&B70, their derivatives and mixtures 
thereof. Such brans are secondary products obtained from 
the decortication of durum wheat caryopses and represent 
particularly suitable and inexpensive substrates. The bran 
derived from the processing of the outer layers of the 
caryopses is removed by preliminary friction and/or abrasion 
operations before the milling of the same. A type of selected 
bran having a high fiber content, obtained from B&B70 was 
also tested, using additional selective steps with the aim of 
ascertaining whether the higher concentration was capable of 
more intensely stimulating growth of fungus, compared to 
the two types of selected bran. The term "enzymatic mix-
ture" is herein used to indicate an extract of microbial culture 
containing at least one type of enzyme. Preferably, the en-
zymatic mixture contains enzymes chosen from the group 
comprising glucanases, xylanases, chitanases and cellulases, 
in particular endoglucanases and endoxylanases. The chosen 
Trichoderma strain is preferably grown on a substrate con-
taining about 1% bran. The solubilization step comprises 
incubation of a reaction mixture comprising bran dispersed 
in distilled water, at a proper temperature. This particular 
composition of enzymes has proven to be surprisingly effec-
tive in the solubilization of insoluble bran fibers, thus allow-
ing to obtain, by means of high concentrations of enzymatic 
extract of fungal origin, a dietary fiber composition com-
posed of soluble fiber even up to 12.5%. It has been surpris-
ingly found out that the dietary fiber composition obtained 
through the method of the present invention is not subjected 
to deterioration in terms of organoleptic properties compared 
to the starting bran. Furthermore, it has the advantage of hav-
ing prebiotic properties and a high polyphenols level that 
could contribute to the protection against free radicals, thus 
playing a key role in atherosclerosis, cardiovascular and 
pulmonary diseases, arthritis and neurological disorders.  
4.3. Prebiotic/Probiotic 
 The document WO2010081913A2 reports the production 
of a composition of plant based material e.g. glucose of ce-
real, obtained by hydrolyzing or transglucosylating glucose, 
hydrolyzing malto-oligosaccharides into glucose, oxidizing 
glucose and removing gluconic acid [52]. The present inven-
tion relates to a process for the production of a prebiotic 
composition, comprising the steps of (a) providing a plant 
based material wherein the plant is selected from the group 
consisting of cereals, legumes, tubers and mixtures thereof, 
wherein said plant based material comprises dietary fiber, 
optionally starchy material and optionally glucose, or 
wherein said plant based material comprises starchy mate-
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rial, and optionally glucose; (b) hydrolyzing or tranglucosy-
lating at least part of the dietary fiber into glucose and into at 
least one non-digestible oligosaccharide and optionally into 
at least one non-digestible polysaccharide, and optionally 
hydrolyzing and transglucosylating at least part of the 
starchy material or part of the malto-oligosaccharides into 
glucose and into at least one non-digestible oligosaccharide; 
(c) oxidizing at least part of the total glucose, consisting of 
said optional glucose of step (a) and said glucose obtained in 
step (b), to gluconic acid or a salt thereof; (d) removing at 
least part of said gluconic acid and/or a salt thereof obtained 
in step (c); thereby obtaining a composition comprising die-
tary fiber and gluconic acid or a salt thereof, wherein said 
dietary fiber comprises at least one non-digestible oligosac-
charide and optionally at least one non-digestible polysac-
charide. 
 The document WO2010051792A1 has for object of the 
invention the use of microtablets containing a dietary sup-
plement e.g. probiotics and prebiotics, and/or a drug, as a 
food additive or feed additive for production of functional 
foods e.g. cookies and fruit bars, or functional feed [53]. In 
addition, the present invention also extends to methods for 
producing functional foods and feeds and also to foods and 
feeds, which comprise microtablets. 
 The document WO2010059022A1 reports the mixture 
for preparing a functional food with symbiotic action com-
prising strain of probiotic, prebiotic and nutrient solution for 
human consumption [54]. This mixture contains at least one 
probiotic strain selected from Lactobacillus, Bifidus, Strep-
tococcus and/or yeasts; at least one prebiotic basically being 
inulin whereunto is added, a simple carbohydrate being glu-
cose and/or a monosaccharide being sugar, and amines being 
vitamin E, pyridoxine chlorohydrate, folic acid, vitamin B12 
and ascorbic acid, and proteins of animal or vegetable origin, 
with or without the presence of the nine essential amino ac-
ids, lipids, preferentially short-chain, omega, and short-chain 
carbohydrates.  
 The patent WO2011017040A1 describes a nutritional 
composition comprising fiber and probiotics [55]. Nutri-
tional composition including fiber blends having a stable 
amount of probiotics and methods of making the nutritional 
composition are provided. In a general embodiment, the pre-
sent disclosure provides a nutritional composition including 
a fiber blend having agglomerated of fiber particulates and 
probiotic with a water activity of less than about 0.15. The 
nutritional composition can be used as pharmaceutical for-
mulation, nutritional formulation, dietary supplement, func-
tional food and beverage product. 
 The document US7897185B1 has for object of invention 
the development of a cream cheese and methods of making it 
[56]. The technique for making the cream cheese product 
comprised: (i) providing a milkfat fluid comprising butterfat; 
(ii) pasteurizing the milkfat fluid; (iii) homogenizing the 
milkfat fluid; (iv) culturing bacteria in the milkfat fluid; (v) 
producing a cream cheese comprising live probiotic bacteria 
cultures.  
 The document US20100303778A1 mentions new Sac-
charomyces cerevisiae strain submitted to the National Col-
lection of Cultures of Microorganisms, useful for preparation 
of food supplement, probiotic, functional food, cosmeceuti-
cal and/or active pharmaceutical ingredient [57]. The inven-
tion relates to novel yeast strains, to the yeasts resulting from 
these strains, to a composition containing at least one Sac-
charomyces cerevisiae yeast and/or derivatives of a yeast 
having a particular interest as a food additive and/or probi-
otic and/or functional food and/or nutraceutic and/or func-
tional ingredient and/or cosmeceutical and/or pharmaceutical 
active agent. The invention also relates to the use in human 
and/or animal nutrition, or for the treatment or prevention of 
inflammatory diseases. 
 The document US20100203018A1 describes zinc-
enriched biomass preparation used as probiotic agent for 
manufacturing probiotic composition (e.g. dietary products) 
by culturing microorganisms consisting of Bifidobacterium 
animalis subsp. lactis and/or Streptococcus thermophilus 
[58]. Furthermore, new microorganism strains are able to 
concentrate zinc within the cell in very high amounts are 
described. 
 The document WO2006039768A1 mentions a functional 
food containing probiotics and prebiotics, optionally as fer-
mented soy-based food or beverage, or sweetened or aroma-
tized, enriched with other functional agents in a balanced 
form [59]. The present invention relates to a fermented func-
tional food based on soy containing probiotics and prebiotics 
and a process of production thereof. The functional food 
contains water-soluble soybean extract, water, probiotics, 
prebiotics, sweetening, optional food additives and func-
tional agents. The process comprises the preparation of the 
inoculum and the fermentation medium, the inoculation with 
the probiotics, the fermentation, the optional treatments, and 
the packaging conditions. 
 The document US7101553B2 describes how to enhance 
immune responses by administration of a composition that 
includes a prebiotic, especially a combination of FOS and 
inulin [60]. The prebiotic carbohydrate formulation has to be 
used for enhancement of immune response and for preven-
tion or treatment of measles. It is well known that prebiotics 
comprise carbohydrates and more specifically, oligosaccha-
rides. Furthermore it is known that they have widely been 
used as functional food ingredients. They resist hydrolysis 
by enzymes of the human digestive tract, can reach the colon 
un-degraded and provide a carbohydrate substance particu-
larly suited to the growth of bifidobacteria. Oligosaccharides 
may be produced from glucose, galactose, xylose, maltose, 
sucrose, lactose, starch, xylan, hemicellulose, inulin, or a 
mixture thereof. Purified commercially available products 
such as fructo-oligosaccharides contain greater than about 
95% solids in the form of oligosaccharides. Measles is a ma-
jor public health problem, infecting approximately 70 mil-
lion children annually, and it is estimated that 2 million die 
each year from the disease itself or its complications. In ad-
dition to fever and rash, the consequences of measles include 
acute diarrhea or dysentery, pneumonia, encephalitis, and 
blindness due to acute vitamin A deficiency. It has been 
found that children fed a diet comprising a prebiotic formu-
lation have a significantly enhanced immune response after 
vaccination than children fed a control diet without this pre-
biotic formulation. In a first aspect the present invention 
provides a composition comprising at least one prebiotic for 
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enhancement of an immune response. In a second aspect, the 
invention provides use of a prebiotic in the manufacture of a 
medicament or nutritional composition for enhancement of 
an immune response. In a third aspect, the invention pro-
vides use of a prebiotic or composition in the manufacture of 
a medicament or nutritional composition for the prevention 
or supportive treatment of measles. In a fourth aspect, the 
invention provides a method of enhancing an immune re-
sponse which comprises administering an effective amount 
of a prebiotic or composition comprising at least one prebi-
otic. In a fifth aspect, the invention provides a method of 
prevention or supportive treatment of diseases such as mea-
sles which comprises administering an effective amount of a 
prebiotic or composition comprising at least one prebiotic. 
The composition may include a probiotic in addition to a 
prebiotic. Preferably, the probiotic is selected from the group 
consisting of Bifidobacterium bifidum and Streptococcus 
thermophilus. Preferably the Bifidobacterium bifidum is Bi-
fidobacterium lactis. An advantage of the present invention 
is that it provides an elevated immune response after vacci-
nation and therefore offers substantial protection until a sec-
ond follow-up vaccine can be administered. Another advan-
tage of the present invention is that it provides an elevated 
response to early measles vaccination, thus offering substan-
tial protection against measles until a second measles vac-
cine is administrated. Moreover, it may be employed to en-
hance an immune response, e.g., protection against measles, 
by simple consumption of food before, during, and after the 
vaccination period. It will be appreciated that intravenous or 
subcutaneous administration of a drug requires expertise, and 
compared to oral administration it is not as safe, convenient 
or acceptable to the patient. In the light of these concerns, the 
invention provides the clear advantage of a nutritional and/or 
therapeutic product, which may be administered orally  
although other forms of administration can be used. In an 
embodiment, the nutritional composition comprises a milk-
based cereal together with a prebiotic formulation. Prefera-
bly, the milk-based cereal is an infant cereal that acts as a 
carrier for the prebiotic formulation. The most preferred  
prebiotic comprises a mixture of fructo-oligosaccharides  
and inulin in the amounts by weight of 70% fructo-
oligosaccharides and 30% inulin. If desired and advanta-
geously, the composition may include a source of protein 
and/or a source of carbohydrate and/or a source of fat. Die-
tary protein is preferred as a source of protein. Dietary fibers 
can be included, if desired and when present, it comprises up 
to about 5% of the weight of the nutritional composition. 
The dietary fibers may be provided from any suitable origin, 
including for example soy, pea, oat, pectin, guar gum, gum 
arabic, FOS or a mixture thereof. Suitable vitamins and min-
erals may be included in the nutritional composition in an 
amount to meet the appropriate or desirable guidelines. The 
nutritional composition for enhancing immune response is 
preferably entirely administrable. If it is desired to produce a 
powdered nutritional formula, the homogenized mixture is 
transferred to a suitable drying apparatus such as a spray 
drier or freeze drier and converted to powder. 
 The document US20100028489A1 reports pre-fermented 
symbiotic matrix useful in pharmaceuticals, cosmetics, and 
foodstuffs e.g. drinks, contains cereals suspension, prefera-
bly oat, with encapsulated microorganisms, encapsulated 
prebiotics, and other food ingredients [61]. Prebiotics and 
their combination with probiotics in an encapsulated form 
are considered as an investment for food the industry, with 
the intention of maintaining their long-term stability and 
optimizing the nutritional qualities of the associated product. 
The present invention's object is also complementing the 
actual functional food market and solving problems inherent 
to the reduced shelf-life period of such foods due to loss of 
probiotic viability to values below the minimum limits 
needed, in order to promote biological activity. Furthermore, 
the present invention aims to improve the fermentative proc-
ess conditions at different levels, reduce energy consump-
tion, risk of contamination as well as promotion of long term 
microbial stability maintenance. The pre-fermented symbi-
otic matrix is designed, in particular, for those cases where 
intolerance and/or allergy to dairy products occur, but it is 
further applicable to the pharmaceutical, cosmetic and pref-
erably food industries, including pet food. The products  
obtained possess sensorial characteristics that are identical to 
those produced by traditional fermentation processes. The 
process reveals a method for the improvement of fermenta-
tive process conditions at several levels such as (i) the con-
tinuous reutilization of the immobilized cells; (ii) the fer-
mentation time reduction contributes to energy saving 
throughout the process, (iii) the reduction of contaminating 
risks and (iv) the long term maintenance of microbial stabil-
ity. 
 The document US20100003370A1 discloses on func-
tional sugar replacement. The invention is related to a func-
tional food ingredient, which replaces sugar on a 1/1 weight 
and/or volume basis in food recipes containing sucrose, with 
a substantial caloric reduction in view [62]. The functional 
food replacement for sucrose, according to the present inven-
tion comprises prebiotic fibers and sweeteners, and possibly 
other non-selective fibers, minerals, vitamins and probiotic 
strains. More particularly, the present invention involves a 
solid or semi-solid functional sweetener that can be used to 
replace sugar in any preparation on a 1/1 weight basis and/or 
additionally on a 1/1 volume basis. Sugar is a popular sweet-
ening additive in human food preparation. Popular feeding 
habits tend to show an over consumption of sugar. However, 
due to its elevated calorie content, high uptake of sugar is not 
recommended for dietary reasons. Further, people with dia-
betes need to control the intake of sugar. A high level of glu-
cose in the blood is harmful. Even though the symptoms are 
not immediately severe, over time, uncontrolled high blood 
sugar levels can damage the smaller blood vessels, leading to 
complications including irreversible damage to the eyes and 
kidneys. Nerves and organs can also be damaged, as well as 
the ability to feel sensations and pain. Uncontrolled diabetes 
increases the risk of cardiovascular diseases such as heart 
attack and stroke. Therefore, sugar replacement solutions for 
popular foodstuffs are of high value. The present invention 
relates to a new concept with respect to healthy nutritional 
habits and functional foods. The basic and most important 
idea for this concept is that people no longer need to change 
their food habits in order to improve their health. Within the 
concept of the invention, it is possible to consume foods with 
positive health effects as simple and effective as possible, 
without giving up anything the consumer likes such as sweet 
or salty taste, palatable structure and texture of the food 
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products. The main goal is to replace those food ingredients 
that are used in the largest quantities, but at the same time 
present an insidious poison to even healthy human beings. 
One of the most important ingredients in this context is 
sugar. In this view, it is important to acknowledge the pres-
ence of complex microflora in the gastrointestinal tract, more 
specifically the colon. In the gastrointestinal tract, microor-
ganisms are prevalent in the colon. It is known that microbes 
in the large intestine complete the digestion process on food 
components that are not digested in the small intestine, such 
as fibers and plant-derived food materials. The characteris-
tics of these oligo- and polysaccharides are dependent on the 
saccharide composition, the bonds between the saccharides 
and the degree of polymerization. 
 Some of these fibers have prebiotic properties and are 
called prebiotic fibers or prebiotic oligo- or polysaccharides. 
They are mainly soluble oligo- and polysaccharides that are 
non digestible, which means that they are neither digested by 
human enzymes of the gastro-intestinal tract nor absorbed in 
the upper digestive tract. Thus, they arrive unchanged in the 
colon where they are at least partially fermented, mainly by 
beneficial bacteria present in the colon, such as Bifidobacte-
ria and Lactobacilli. Hence, these beneficial bacteria utilize 
pre-biotic fibers as selective energy source for growth and 
proliferation in the colon. This effect is called prebiotic ac-
tivity, referring to stimulation and/or activation of health 
promoting bacteria in the intestinal tract. Studies on humans 
have, for instance, confirmed that ingestion of moderate 
amounts of these pre-biotic fibers (from 5 g per day) results 
in a significant increase (up to 10 fold) of Bifidobacteria in 
the colon. During fermentation, these fibers are degraded and 
short chain fatty acids are produced, lowering pH levels and 
providing an energy source for growth and maintenance of 
large intestine cells. This process leads to differentiation of 
cancer cells, a vital step that is required before cancer cells 
can be killed. The pH lowering effect of the acid production 
results in an improved calcium and magnesium uptake, and 
simultaneously creates a harmful environment for pathogenic 
and putrefactive bacteria, such as Clostridia, E. coli or  
Bacteroides. Replacement of sugar by intense sweeteners is 
a serious problem in solid and semi-solid comestibles, be-
cause sucrose fulfils both a structural and sweetening func-
tion in these products. Preparation of low sugar or no sugar 
added products automatically faces the problem of replacing 
the bulk material in the product, which, in addition, should 
have at least the same functionality as the replaced sugar. 
Moreover, said replacement should provide essentially the 
same sweetness as sugar, at least the same functional effects 
as sugar on structure, texture, appearance and palatability of 
food preparation, but should also have some additional func-
tionality such as health promoting effects and/or increased 
shelf life of processed products. Accordingly, the sugar sub-
stitute should not only replace sugar but should additionally 
offer a wide range of health effects while providing the hu-
man body with the required amounts of fibers, vitamins and 
minerals. To sum up, it can be stated that by using the sugar 
substitute, a better health should be obtained without making 
any concessions on neither taste nor structure. Preferably, at 
least one component of the bulking fiber composition is pre-
biotic. Moreover, it is preferred that at least one component 
is composed of mainly glucose units and at least one compo-
nent is composed of mainly fructose units. 
 The document US20060252725A1 describes the use of 
prebiotics to prepare food, nutraceutical or pharmaceutical 
products for preventing or treating oxidative stress, espe-
cially caused by high fructose consumption [63]. The inven-
tion relates to the use of prebiotics for the preparation of 
food formulations, functional foods, or pharmaceutical com-
positions for preventing or treating oxidative stress in par-
ticular linked to the consumption of fructose. The invention 
also relates to a food preparation comprising simple carbo-
hydrates, in particular fructose, in combination with prebiot-
ics. A subject of the present invention is the use of prebiotics 
for preparation of functional compositions intended to pre-
vent or treat oxidative stress, as the result of an imbalance in 
favor of pro-oxidant species relative to anti-oxidant species. 
Pro-oxidant species are generally free radicals and in particu-
lar oxygenated free radicals. Moreover, during inflammatory 
reaction, the stimulation of the phagocytes is also accompa-
nied by the formation of free radicals. The anti-oxidant de-
fenses of the organism use protein systems, such as superox-
ide dismutase, but also anti-oxidant compounds provided by 
food, such as vitamins C and E, or other nutrients, such as 
carotenoids, polyphenols or flavonoids. The inventors have 
in particular shown that foods that are too rich in sugars, and 
in particular in saccharose [64] and fructose [65], could 
cause significant oxidative stress. Because of their low pro-
duction costs, syrups that are rich in fructose produced from 
corn are preferably used in sugary drinks. While fructose is 
naturally present in honey and in fruits where it is associated 
with many protective micronutrients, the consequences of an 
unrestricted increase of this carbohydrate in purified form on 
health are questionable. In fact, fructose has many properties 
that distinguish it from other sugars and the high intake of 
this carbohydrate could be responsible for undesirable meta-
bolic effects. The present invention demonstrates that prebi-
otics and more particularly FOS can combat the oxidative 
stress resulting from an excess of fructose in food. The in-
ventors have shown that the addition of prebiotics to the food 
intake, advantageously the addition of FOS, allowed a reduc-
tion in oxidative stress due in particular to a diet rich in sug-
ars, and in particular fructose.  
 The document EP0998206A1 reports the nutritional sup-
plement based on FOS and phyto-estrogens for treatment of 
menopause symptoms and prevention of osteoporosis [66]. 
The invention relates to a food preparation comprising a 
vegetal substance containing phyto-estrogen, consisting of 
crushed flaxseed containing lignan and soya flour containing 
isoflavonoids. In addition, the preparation contains a FOS 
with a prebiotic effect, such as inulin. The phyto-estrogen of 
the preparation is intended to act on menopause symptoms in 
women, and the purpose of FOS is to enhance intestinal ac-
tivity by increasing the growth of Bifidobacteria in the intes-
tines, thus promoting phyto-estrogen conversion and absorp-
tion in the intestines. In accordance with the invention, the 
preparation is a mixture of components in the form of a solid 
such as a mixture consisting of soya flour, crushed flaxseed, 
FOS and a flavoring and coloring vegetal substance, such as 
dried rosehip or lingonberry, that can be mixed to form a 
drink. 
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 Soya has the characteristic of containing phyto-estrogens 
in abundance, more specifically daidzein and genistein, be-
longing to the isoflavonoids. Phyto-estrogens are hormone-
like compounds occurring naturally in certain plants and 
greatly resembling the estrogens produced by the female 
organism. It is known that vegetal phyto-estrogens are con-
verted in the intestines by the fermentation maintained by 
intestinal bacteria into substances having a similar effect as 
that of the estrogens produced by human organism. Thus, it 
is possible to alleviate problems connected with the meno-
pause in women by adding phyto-estrogens to the food, sub-
stituting these for synthetic estrogen drugs. As a matter of 
fact, in countries where the food traditionally contains soy-
bean products in abundance, women have significantly less 
menopause symptoms than in countries where the food is 
poor in phyto-estrogens. Phyto-estrogens prevent "hot 
flushes", prevent vaginal dryness and have also been con-
firmed to have an anti-depressive effect. Phyto-estrogens 
also delay bone fragility, thus reducing the risk of contract-
ing osteoporosis. Except in soya, there is an abundance of 
phyto-estrogens in flaxseed, which contains secoisolaricires-
inol and matairesinol belonging to lignans. In addition, many 
other plants, such as some cereal crops, contain phyto-
estrogens in minor concentrations. Owing to the known ef-
fects of phyto-estrogens mentioned above, there is an abun-
dance of functional food preparations on the market, in 
which especially soya, but also flaxseed constitute a chief 
ingredient. A typical preparation consists of vegetal ingredi-
ents in the form of a finely or coarsely divided powder that 
contains soya flour or crushed flaxseed, or preferably both, 
and it is intended as a drink mixed in a liquid. Such a par-
ticulate preparation can also be used as a supplement to be 
mixed in other foodstuffs, such as yoghurt and various cere-
als and flakes. Besides phyto-estrogens, the preparation is 
rich in fibers and poly-unsaturated fatty acids, thus allowing 
the need for synthetic estrogen drugs to be avoided during 
the menopause. The invention aims at the joint effect of 
fructo-oligosaccharides and phyto-estrogens, so that the 
growth of useful Bifidobacteria in the intestines enhances the 
intestinal activity and thus boosts the conversion of phyto-
estrogens into a form usable by the intestines and their ab-
sorption into the human body. Moreover, a special purpose 
of the invention is to provide a preparation that is easy to use 
as a food supplement, mixed in various foodstuffs or drinks. 
Thus, this preparation is characterized by being a mixture of 
components in the form of solid, finely divided particles, 
which contains FOS with a prebiotic effect combined with a 
vegetal substance containing phyto-estrogens, which consists 
of soya flour containing flavonoids and crushed flaxseed 
containing lignan. The preparation of the invention can be 
prepared by mixing vegetal components for instance in wa-
ter, sour milk or juice, forming a drink consumed as such. 
With the adequate use of crushed flaxseed containing lignans 
and soya flour containing isoflavonoids, the phyto-estrogen 
concentration can be controlled within a proper range. 
5. CURRENT & FUTURE DEVELOPMENTS 
 The high potential that functional foods can achieve on 
the world market is determined by the fact that the driving 
force of this sector is mainly the increasing basic awareness 
of the metabolic and physiological action of natural com-
pounds, which bring better health benefits than conventional 
products when added to foods or when naturally present in 
them. The nutraceutical sector has become one of the most 
dynamic segments of the food industry. Many companies 
have invested in development, production and marketing of 
nutraceuticals. As the need to meet new challenges and new 
enquiries by consumers is increasing, the development of 
processes focused on optimisation of nutrition and improve-
ment of eating habits also increases, the production of func-
tional food is prevalently covered by multinational compa-
nies. On the other hand, SMEs are mostly active in the pro-
duction on “niche-food products”, even if the business op-
portunities in that field is continuously increasing. The com-
panies recognize the opportunity and urgency of aiming to-
wards strengthening the tendency for innovation as a vehicle 
for the completion and/or consolidation of the process of 
internationalization, and towards the implementation of net-
work and production chain integration strategies. The soar-
ing of public health costs and the dissemination of preven-
tive medicine are pulling consumers to deepen their knowl-
edge of relations between food, health and well being. Con-
sumers are increasingly aware about reducing health risks 
and improving their lifestyle through more correct eating 
habits. This awareness is also due to research results on food 
antioxidants, beneficial substances found in vegetables and 
crops, and probiotic microorganims. Functional foods are 
rich in many bioactive compounds, most of which shows 
antioxidant and/or anti-carcinogenic and anti-inflammatory 
properties. Particularly, anti-carcinogenic activity of those 
compounds is mediated by several molecular pathways, like 
antioxidant, anti-mutagenic activity, stimulation of immune 
defence system, modulation of antioxidant enzymes, modu-
lation of hormonal system and genetic expression regulation 
in cell growth and apoptosis. Although these molecules are 
considered to possess chemo-preventive activity, their exact 
biochemical function is still unclear. Food nutritional quali-
ties are determined by their natural constituents and compo-
nents that are produced during processing and storing. 
Moreover, the increasing demand of fortified foods is raising 
new issues about the level of micronutrients and supplement 
ingestion, in terms of efficiency and food safety. An addi-
tional element of product innovation could be its optimiza-
tion by micro and nano encapsulation. In fact, many func-
tional ingredients are sensitive to environmental factors such 
as light, moisture, heat, etc. Moreover, if used for enrichment 
of cooked products may be damaged during the different 
stages of production. The functional ingredients may also 
react with other food components and/or add colors, aromas 
and undesirable flavors. For this reason, encapsulation can 
protect the component from mechanical and thermal damage. 
Further innovative elements concern development of alterna-
tive processes to traditional solvent extraction technology. 
The assessment of the nutraceutical quality of the elements 
and their preservation during storage is also a key aspect for 
a functional food. This will lead to identify the critical condi-
tions for maintaining phytocomplexes properties in the final 
product (temperature, humidity, interaction of bioactive 
compounds with food matrices, etc.). Finally, cerebral 
mechanisms of subjective perception of functional foods and 
homeostasis of weight failure by many people are still un-
known. 
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